MNOV · Insider Trading
Medicinova, Inc.
Every open-market purchase and sale reported by MNOV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-29 | 3D Investment Partners Pte. Ltd. | — | Sell | −1,280,000 | −$3.46M |
| 2026-06-25 | Hideki Nagao | Director | A | +44,500 deriv. | — |
| 2026-06-25 | Carolyn Beaver | Director | A | +44,500 deriv. | — |
| 2026-06-25 | Nicole Lemerond | Director | A | +44,500 deriv. | — |
| 2026-01-20 | Yuichi Iwaki | President and CEO | A | +450,000 deriv. | — |
| 2026-01-20 | Kazuko Matsuda | Chief Medical Officer | A | +350,000 deriv. | — |
| 2025-06-20 | Nicole Lemerond | Director | A | +20,000 deriv. | — |
| 2025-06-20 | Hideki Nagao | Director | A | +20,000 deriv. | — |
| 2025-06-20 | Carolyn Beaver | Director | A | +20,000 deriv. | — |
| 2025-02-14 | Hideki Nagao | Director | A | +24,500 deriv. | — |
| 2025-02-14 | Yuichi Iwaki | President and CEO | A | +100,000 deriv. | — |
| 2025-02-14 | Nicole Lemerond | Director | A | +24,500 deriv. | — |
| 2025-02-14 | Kazuko Matsuda | Chief Medical Officer | A | +100,000 deriv. | — |
| 2025-02-14 | Carolyn Beaver | Director | A | +24,500 deriv. | — |
| 2025-01-10 | Kazuko Matsuda | Chief Medical Officer | A | +300,000 deriv. | — |
| 2025-01-10 | Yuichi Iwaki | President and CEO | A | +400,000 deriv. | — |
| 2024-06-12 | Hideki Nagao | Director | A | +20,000 deriv. | — |
| 2024-06-12 | Nicole Lemerond | Director | A | +20,000 deriv. | — |
| 2024-06-12 | Carolyn Beaver | Director | A | +20,000 deriv. | — |
| 2024-01-11 | Geoffrey OBrien | Vice President | A | +84,000 deriv. | — |
| 2024-01-11 | Kazuko Matsuda | Chief Medical Officer | A | +157,500 deriv. | — |
| 2024-01-11 | Yuichi Iwaki | President and CEO | A | +210,000 deriv. | — |
| 2023-08-08 | Nicole Lemerond | Director | A | +18,333 deriv. | — |
| 2023-06-15 | Hideki Nagao | Director | A | +20,000 deriv. | — |
| 2023-06-15 | Carolyn Beaver | Director | A | +20,000 deriv. | — |
| 2023-01-25 | Yuichi Iwaki | President and CEO | A | +235,125 deriv. | — |
| 2023-01-25 | Kazuko Matsuda | Chief Medical Officer | A | +149,625 deriv. | — |
| 2023-01-25 | Geoffrey OBrien | Vice President | A | +76,950 deriv. | — |
| 2022-11-30 | Hideki Nagao | Director | Sell | −6,754 | −$15.20K |
| 2022-11-23 | Hideki Nagao | Director | Sell | −5,583 | −$12.16K |
| 2022-11-21 | Hideki Nagao | Director | Sell | −309 | −$674 |
| 2022-06-17 | Hideki Nagao | Director | A | +20,000 deriv. | — |
| 2022-06-17 | Carolyn Beaver | Director | A | +20,000 deriv. | — |
| 2022-01-31 | Kazuko Matsuda | Chief Medical Officer | A | +192,500 deriv. | — |
| 2022-01-31 | Geoffrey OBrien | Vice President | A | +99,000 deriv. | — |
| 2022-01-31 | Yuichi Iwaki | President and CEO | A | +302,500 deriv. | — |
| 2021-08-25 | Kazuko Matsuda | Chief Medical Officer | M | +60,000 | +$138.00K |
| 2021-07-23 | Yuichi Iwaki | President and CEO | M | +39,583 | +$100.54K |
| 2021-06-28 | Kazuko Matsuda | Chief Medical Officer | M | +102,804 | +$256.62K |
| 2021-06-21 | Carolyn Beaver | Director | A | +20,000 deriv. | — |
| 2021-06-21 | Hideki Nagao | Director | A | +20,000 deriv. | — |
| 2021-05-20 | Geoffrey OBrien | Vice President | M | +43,318 | +$109.12K |
| 2021-04-26 | Federico C.A. Gaeta | Chief Scientific Officer | A | +24,000 deriv. | — |
| 2021-03-15 | Hideki Nagao | Director | Sell | −2,354 | −$17.42K |
| 2021-03-01 | Yuichi Iwaki | President and CEO | M | +86,250 | +$212.18K |
| 2021-02-04 | Kazuko Matsuda | Chief Medical Officer | A | +325,000 deriv. | — |
| 2021-02-04 | Geoffrey OBrien | Vice President | A | +99,000 deriv. | — |
| 2021-02-04 | Yuichi Iwaki | President and CEO | A | +495,000 deriv. | — |
| 2020-10-22 | Carolyn Beaver | Director | A | +15,000 deriv. | — |
| 2020-09-16 | Hideki Nagao | Director | Sell | −1,000 | −$5.78K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| 3D Investment Partners Pte. Ltd. | — | 4,862,047 | $6.81M |
| Yuichi Iwaki | President and CEO | 1,091,933 | $1.53M |
| Kazuko Matsuda | Chief Medical Officer | 322,996 | $452.19K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MNOV quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.